Dose-Related Safety and Immunogenicity of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults

Publication Type
Journal Article
Year of Publication
2006
Authors
Treanor, JJ; Schiff, GM; Couch, RB; Cate, TR; Brady, RC; Hay, CM; Wolff, MC; She, D; Cox, MJC
Secondary
J Infec Dis
Volume
193
Start Page
1223
Pagination
1223-1228
Date Published
05/2006
Keywords
Antibodies-Viral; Baculoviridae; Dose-Response Relationship-Immunologic; Hemagglutinin Glycoproteins- Influenza Virus; Influenza Vaccines; Maximum Tolerated Dose; trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine; Vaccines-Inactivated
ISBN
00221899
Abstract
BACKGROUND: Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS: In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS: Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA. CONCLUSIONS: Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
URL
http://www.ncbi.nlm.nih.gov/pubmed/16586358